Skip to main content (Press Enter).
Member Login
Skip auxiliary navigation (Press Enter).
Contact Us
renalhealthcare.org
Skip main navigation (Press Enter).
Toggle navigation
Search Options
COVID-19 Hub
Communities
All Discussions
All Communities
My Communities
Open Member Community
AKI, Billing & Reimbursement
Regional Communities
Staffing
Quality
Survey Preparedness
Directory
Member Directory
Participate
Join a Community
Join A Committee
Resources
Community FAQs
Renal Services Exchange
Renew Your Membership
Education Station
Events
Event Description
Spotlight: Korsuva ™ - The 1st and only FDA-Approved Treatment for CKD-Associated Pruritus
When:
Feb 3, 2022 from 01:00 PM to 02:00 PM (ET)
Associated with
Open Member Community
share:
Korsuva ™ (Difelikefalin):
The 1
st
and only FDA-approved treatment for moderate to severe CKD-associated pruritus in adult hemodialysis patients
February 3, 2022
1:00 PM ET
The webinar will provide education around CKD-associated pruritus and the impact on the lives of hemodialysis patients. Also, we will be sharing clinical information on recently approved Korsvuva, the first and only FDA-approved treatment for moderate to severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD).
Learning Objectives
What is chronic kidney disease-associated pruritus?
Clinical study results of Korsuva ™ (Difelikefalin)
Overview of Korsuva ™ (Difelikefalin) reimbursement
More information
Location
Online Instructions:
Url:
http://www.pathlms.com/renal-healthcare-association/courses/38744
Login:
Download to Your Calendar
Skip Navigation Links
COVID-19 Hub
Communities
Directory
Participate
Resources
Copyright 2022 Connect. All rights reserved.
Powered by Higher Logic